The serotonin syndrome

American Journal of Psychiatry

Volumn 148, Issue 6, 1991, Pages 705-713

  Sternbach, Harvey ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 METHOXY N,N DIMETHYLTRYPTAMINE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CITALOPRAM; CLOMIPRAMINE; CLORGYLINE; FLUOXETINE; LEVODOPA; LITHIUM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SELEGILINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; TRANYLCYPROMINE; TRYPTOPHAN;

ADULT; ADVERSE DRUG REACTION; CLINICAL ARTICLE; CONFUSION; DRUG INTERACTION; FEMALE; HUMAN; MALE; MYOCLONUS; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; TREMOR;

ADULT; ANTIDEPRESSIVE AGENTS; BASAL GANGLIA DISEASES; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUOXETINE; HUMAN; MALE; MONOAMINE OXIDASE INHIBITORS; NEUROLEPTIC MALIGNANT SYNDROME; RECEPTORS, SEROTONIN; SEROTONIN; TRYPTOPHAN;

EID: 0025869797     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.148.6.705     Document Type: Article

References (67)

1. Rapport MM, Green AA, Page IH: Serum vasoconstrictor (serotonin), IV: isolation and characterization. J Biol Chem 1948; 176:1243-1251
2. Drugs acting on 5-hydroxytryptamine receptors (editorial). Lancet 1989; 2:717-719
3. Smith B, Prockop DJ: Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. N Engl J Med 1962; 267:1338-1341
4. Curzon G, Ettlinger G, Cole M, et al: The biochemical, behavioral and neurologic effects of high L-tryptophan intake in the rhesus monkey. Neurology 1963; 12:431-438
5. Oates JA, Sjoerdsma A: Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 1960; 10:1076-1078
6. Hess SM, Redfield BG, Udenfriend S: The effect of monoamine oxidase inhibitors and tryptophan on the tryptamine content of animal tissues and urine. J Pharmacol Exp Ther 1959; 127: 178-181
7. Bogdanski DF, Weissbach H, Udenfriend S: Pharmacological studies with the serotonin precursor 5-hydroxytryptophan. J Pharmacol Exp Ther 1958; 122:182-194
8. Hodge JV, Dates JA, Sjoerdsma A: Reduction of the central effects of tryptophan by a decarboxylase inhibitor. Clin Pharmacol Ther 1964; 5:149-155
9. Pare CMB, Sandier M: A clinical and biochemical study of a trial of iproniazid in the treatment of depression. J Neurol Neurosurg Psychiatry 1959; 22:247-251
10. Coppen A, Shaw DM, Farrell MB: Potentiation of the antidepressive effect of a monoamine oxidase inhibitor by tryptophan. Lancet 1963; 1:79-81
11. Pare CMB: Potentiation of monoamine-oxidase inhibitors by tryptophan. Lancet 1963; 2:527-528
12. Kline NS, Sacks W, Simpson GM: Further studies on one day treatment of depression with 5-HTP. Am J Psychiatry 1964; 121:379-381
13. Glassman A, Platman SR: Potentiation of a monoamine oxidase inhibitor by tryptophan. Psychiatr Res 1969; 7:83-88
14. Beaumont G: Drug interactions with clomipramine (Anafranil). J Int Med Res 1973; 1:480-484
15. White K, Simpson G: Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981; 1:264-281
16. Gerson SC, Baldessarini RJ: Motor effects of serotonin in the central nervous system. Life Sci 1980; 27:1435-1451
17. Baloh RW, Dietz J, Spooner JW: Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol 1982; 11:95-97
18. Insel TR, Roy BF, Cohen RM, et al: Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139:954-955
19. Thomas JM, Rubin EH: Case report of a toxic reaction from a combination of tryptophan and phenelzine. Am J Psychiatry 1984; 141:281-283
20. Pope HG Jr, Jonas JM, Hudson JI, et al: Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 1985; 142:491-492
21. Levy AB, Bucher P, Votolato N: Myoclonus, hyperreflexia and diaphoresis in patient on phenelzine-tryptophan combination treatment. Can J Psychiatry 1985; 30:434-436
22. Guze BH, Baxter LR Jr: The serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 1986; 6:119-120
23. Price WA, Zimmer B, Kucas P: Serotonin syndrome: a case report. Clin Pharmacol 1986; 26:77-78
24. Steiner W, Fontaine R: Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports. Biol Psychiatry 1986; 21:1067-1071
25. Sandyk R: L-Dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine (letter). J Clin Psychopharmacol 1986; 6:194-195
26. Sternbach H: Danger of MAOI therapy after fluoxetine withdrawal (letter). Lancet 1988; 2:850
27. Kline SS, Mauro LS, Scala-Barnett DM, et al: Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8:510-514
28. Feighner JP, Boyer WF, Tyler DL, et al: Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51:222-225
29. Green AR, Kelly PH: Evidence concerning involvement of 5-hydroxytryptamine in locomotor activity produced by amphetamine or tranylcypromine-L-DOPA. Br J Pharmacol 1976; 57: 141-147
30. Deakin JFW, Green AR: The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol 1978; 64:201-209
31. Peroutka SJ, Snyder SH: Multiple serotonin receptors: differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Mol Pharmacol 1979; 16: 687-699
32. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science 1981; 212:827-829
33. Gonzales-Heydrich J, Peroutka SJ: Serotonin receptor and reuptake sites: pharmacological significance. J Clin Psychiatry 1990; 51(April suppl):5-12
34. Lucki I, Nobler MS, Frazer A: Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther 1984; 1:133-139
35. Goodwin GM, De Souza RJ, Green AR, et al: The pharmacology of the behavioural and hypothermic responses of rats to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Psychopharmacology (Berlin) 1987; 91:506-511
36. Yamada J, Sugimoto Y, Horisaka K: The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur J Pharmacol 1988; 154:299-304
37. Smith LM, Peroutka SJ: Differential effects of 5-hydroxytryptamine la selective drugs on the 5-HT behavioral syndrome. Pharmacol Biochem Behav 1986; 24:1513-1519
38. Yamada J, Sugimoto Y, Horisaka K: The evidence for the involvement of the 5-HT1A receptor in 5-HT syndrome induced in mice by tryptamine. Jpn J Pharmacol 1989; 51:421-424
39. Molliver ME: Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 1987; 7:3S-23S
40. Graham PM, Ilett KF: Danger of MAOI therapy after fluoxetine withdrawal (letter). Lancet 1988; 2:1255-1256
41. Blier P, de Montigny C, Chaput Y: A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 1990; 51(April suppl): 14-20
42. Sleight AJ, Marsden CA, Martin KF, et al: Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan. Br J Pharmacol 1988; 93:303-310
43. Stack CG, Rogers P, Linter SPK: Monoamine oxidase inhibitors and anaesthesia. Br J Anaesth 1988; 60:222-227
44. Wells DG, Bjorksten AR: Monoamine oxidase inhibitors revisited. Can J Anaesth 1989; 36:64-74
45. Brennan D, MacManus M, Howe J, et al: "Neuroleptic malignant syndrome" without neuroleptics (letter). Br J Psychiatry 1988; 152:578-579
46. Rosebush P, Stewart T: A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 146: 717-725
47. Expanded recall for L-tryptophan. FDA Drug Bull 1990; 20(April):2-3
48. Yamawaki S, Yanagawak K, Hotta I, et al: Effect of long-term lithium treatment on serotonin syndrome in rats. Yakubutsu Seishin Kodo 1986; 6:247-252
49. Goodwin GM, De Souza RJ, Wood AJ, et al: The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berlin) 1986; 90:488-493
50. Marley E, Wozniak KM: Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 1984; 18:173-189
51. Bieck PR, Antonin KH: Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychopharmacol 1988; 8:237-245
52. Dickinson SL, Curzon G: Roles of dopamine and 5-hydroxytryptamine in stereotyped and non-stereotyped behavior. Neuropharmacology 1983; 22:805-812
53. Bernick C: Methysergide-induced akathisia. Clin Neuropsychopharmacology 1982; 11:87-89
54. Neppe VM: The clinical neuropharmacology of buspirone, in Innovative Psychopharmacotherapy. Edited by Neppe VM. New York, Raven Press, 1989
55. Neppe VM: High-dose buspirone in case of tardive dyskinesia (letter). Lancet 1989; 2:1458
56. Hjorth S, Carlsson A: Buspirone: effects on central monoaminergic transmission - possible relevance to animal experimental and clinical findings. Eur J Pharmacol 1982; 83:299-303
57. Eison AS, Eison MS, Stanley M, et al: Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav 1986; 24:701-707
58. Trulson ME, Jacobs BL: Behavioral evidence for rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol 1976; 36:149-154
59. Garattinis K, Caccia S, Mennini T, et al: The mechanism of action of fenfluramine. Postgrad Med 1975; 5:27-34
60. Hunsinger RN, Wilson MC: A comparison of the fenfluramine-induced serotonergic syndrome in rats subacutely treated with either saline or d-amphetamine. Pharmacol Res Commun 1984; 16:579-588
61. Hollander E, DeCaria CM, Schneier FR, et al: Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 1990; 51:119-123
62. Brown TCK, Cass NM: Beware - the use of MAO inhibitors is increasing again. Anaesth Intensive Care 1979; 7:65-68
63. Rivers N, Horner B: Possible lethal reaction between Nardil and dextromethorphan (letter). Can Med Assoc J 1970; 103:85
64. Hansen TE, Dieter K, Keepers GA: Interaction of fluoxetine and pentazocine (letter). Am J Psychiatry 1990; 147:949-950
65. Marley E, Wozniak KM: Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline reuptake. J Psychiatr Res 1984; 18:191-203
66. Weinstock M, Weiss C, Gitter S: Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenocepter antagonists. Neuropharmacology 1977; 16:273-276
67. Sprouse JS, Aghajanian GK: (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol 1986; 128:295-298